Building access to the Regenstrief Institute is currently restricted. More on our coronavirus precautions.
See our coronavirus precautions.

The Omicron variant of COVID-19 quickly became the dominant strain in the United States, and new data regarding its symptoms, transmissibility and severity are constantly being released.  

Through multiple media interviews, Regenstrief Institute Vice President for Data and Analytics Shaun Grannis, M.D., M.S., and Director of Public Health Informatics Brian Dixon, PhD, MPA,  are providing context to the new information, explaining the available data and what is still unknown.  

Research scientists and data teams from the institute continue to work with the U.S. Centers for Disease Control and Prevention (CDC)’s VISION Network to use real-world data to analyze the effectiveness of COVID-19 vaccines against variants such as Omicron.  The VISION Network is made up of seven organizations across the country — including Regenstrief — that submit real-world data from electronic medical records and public health records. 

Past findings from the network published by Regenstrief faculty include a New England Journal of Medicine paper on the effectiveness of vaccinations at protecting against COVID-related hospitalizations and death as well as CDC Morbidity and Mortality Weekly papers on vaccine effectiveness against the Delta variant, vaccine effectiveness compared to infection-induced immunity and vaccine effectiveness among immunocompromised adults 

As the COVID-19 situation rapidly changes, real-world data such as that gathered by the VISION Network remain one of the best tools to understand the ongoing pandemic and develop strategies to contain the virus.  

Related Influence

May 03, 2022 • Influence
Regenstrief researcher participates in expert panel discussion on life sciences and business climate
Topics included EHRs, wellness, COVID dashboard Regenstrief Research Scientist NiCole Keith, PhD, took part in a broad discussion among life sciences leaders on Friday, April 29, 2022 at the downtown Indianapolis Westin hotel. The expert panel discussion was hosted by the Indianapolis Business Journal as part of the IBJ Power Breakfast Series. In addition to Dr.…
Continue Reading >
Apr 18, 2022 • Influence
Research from Regenstrief gastroenterologist makes impact; article recognized by professional journal as 1 of most widely cited for 2020-2021
Regenstrief Institute Research Scientist Thomas Imperiale, M.D., is being recognized by the American Association for Cancer Research for an impactful paper. His article “Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study” was one of the most highly cited papers in the Journal of Cancer Prevention…
Continue Reading >